Fast and robust next-generation sequencing technique using ion torrent personal genome machine for the screening of neurofibromatosis type 1 (NF1) gene. 2014

Bernadett Balla, and Kristóf Árvai, and Péter Horváth, and Bálint Tobiás, and István Takács, and Zsolt Nagy, and Magdolna Dank, and György Fekete, and János P Kósa, and Péter Lakatos
First Department of Internal Medicine, Semmelweis University, 1083 Korányi S. u 2/a, Budapest, Hungary, balladetti@gmail.com.

Neurofibromatosis type 1 (NF1) gene exhibits one of the highest spontaneous mutation rates in the human genome. Identification of the NF1 mutation is challenging because the NF1 gene is very large and complex, lacking mutational "hot spots." There is no clustering of mutations, there are several pseudogenes, and a wide spectrum of different types of mutation has been recognized. To date, NF1 mutations or deleted regions have been detected with a number of techniques. With the appearance of next-generation sequencing (NGS) machines, molecular biology is in a new revolutionary phase. Our aim was to work out a method to use the high-throughput NGS machine, Ion Torrent PGM, in diagnostic settings for neurofibromatosis type 1. In our examination, we could reveal 21 distinct variations in NF1 gene in seven patients. This is an absolutely new method for exploring the genetic background of neurofibromatosis type 1 exhibiting the extremely high throughput of NGS in a diagnostic setting.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009456 Neurofibromatosis 1 An autosomal dominant inherited disorder (with a high frequency of spontaneous mutations) that features developmental changes in the nervous system, muscles, bones, and skin, most notably in tissue derived from the embryonic NEURAL CREST. Multiple hyperpigmented skin lesions and subcutaneous tumors are the hallmark of this disease. Peripheral and central nervous system neoplasms occur frequently, especially OPTIC NERVE GLIOMA and NEUROFIBROSARCOMA. NF1 is caused by mutations which inactivate the NF1 gene (GENES, NEUROFIBROMATOSIS 1) on chromosome 17q. The incidence of learning disabilities is also elevated in this condition. (From Adams et al., Principles of Neurology, 6th ed, pp1014-18) There is overlap of clinical features with NOONAN SYNDROME in a syndrome called neurofibromatosis-Noonan syndrome. Both the PTPN11 and NF1 gene products are involved in the SIGNAL TRANSDUCTION pathway of Ras (RAS PROTEINS). Peripheral Neurofibromatosis,Recklinghausen Disease of Nerve,von Recklinghausen Disease,Cafe-au-Lait Spots with Pulmonic Stenosis,Molluscum Fibrosum,NF1 (Neurofibromatosis 1),Neurofibromatosis I,Neurofibromatosis Type 1,Neurofibromatosis Type I,Neurofibromatosis, Peripheral Type,Neurofibromatosis, Peripheral, NF 1,Neurofibromatosis, Peripheral, NF1,Neurofibromatosis, Type 1,Neurofibromatosis, Type I,Pulmonic Stenosis with Cafe-au-Lait Spots,Recklinghausen Disease, Nerve,Recklinghausen's Disease of Nerve,Recklinghausens Disease of Nerve,Watson Syndrome,von Recklinghausen's Disease,Cafe au Lait Spots with Pulmonic Stenosis,Neurofibromatoses, Peripheral,Neurofibromatoses, Type I,Neurofibromatosis, Peripheral,Peripheral Neurofibromatoses,Pulmonic Stenosis with Cafe au Lait Spots,Syndrome, Watson,Type 1 Neurofibromatosis,Type 1, Neurofibromatosis,Type I Neurofibromatoses,Type I, Neurofibromatosis,von Recklinghausens Disease
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015894 Genome, Human The complete genetic complement contained in the DNA of a set of CHROMOSOMES in a HUMAN. The length of the human genome is about 3 billion base pairs. Human Genome,Genomes, Human,Human Genomes
D017422 Sequence Analysis, DNA A multistage process that includes cloning, physical mapping, subcloning, determination of the DNA SEQUENCE, and information analysis. DNA Sequence Analysis,Sequence Determination, DNA,Analysis, DNA Sequence,DNA Sequence Determination,DNA Sequence Determinations,DNA Sequencing,Determination, DNA Sequence,Determinations, DNA Sequence,Sequence Determinations, DNA,Analyses, DNA Sequence,DNA Sequence Analyses,Sequence Analyses, DNA,Sequencing, DNA
D057285 Precision Medicine Clinical, therapeutic and diagnostic approaches to optimal disease management based on individual variations in a patient's genetic profile. Individualized Medicine,Predictive Medicine,P Health,P-Health,Personalized Medicine,Theranostics,Medicine, Individualized,Medicine, Personalized,Medicine, Precision,Medicine, Predictive,Theranostic

Related Publications

Bernadett Balla, and Kristóf Árvai, and Péter Horváth, and Bálint Tobiás, and István Takács, and Zsolt Nagy, and Magdolna Dank, and György Fekete, and János P Kósa, and Péter Lakatos
September 2013, Forensic science international. Genetics,
Bernadett Balla, and Kristóf Árvai, and Péter Horváth, and Bálint Tobiás, and István Takács, and Zsolt Nagy, and Magdolna Dank, and György Fekete, and János P Kósa, and Péter Lakatos
December 2013, Forensic science international. Genetics,
Bernadett Balla, and Kristóf Árvai, and Péter Horváth, and Bálint Tobiás, and István Takács, and Zsolt Nagy, and Magdolna Dank, and György Fekete, and János P Kósa, and Péter Lakatos
April 2018, Oncology letters,
Bernadett Balla, and Kristóf Árvai, and Péter Horváth, and Bálint Tobiás, and István Takács, and Zsolt Nagy, and Magdolna Dank, and György Fekete, and János P Kósa, and Péter Lakatos
February 2016, Regulatory toxicology and pharmacology : RTP,
Bernadett Balla, and Kristóf Árvai, and Péter Horváth, and Bálint Tobiás, and István Takács, and Zsolt Nagy, and Magdolna Dank, and György Fekete, and János P Kósa, and Péter Lakatos
December 2016, Clinica chimica acta; international journal of clinical chemistry,
Bernadett Balla, and Kristóf Árvai, and Péter Horváth, and Bálint Tobiás, and István Takács, and Zsolt Nagy, and Magdolna Dank, and György Fekete, and János P Kósa, and Péter Lakatos
February 2017, European journal of medical genetics,
Bernadett Balla, and Kristóf Árvai, and Péter Horváth, and Bálint Tobiás, and István Takács, and Zsolt Nagy, and Magdolna Dank, and György Fekete, and János P Kósa, and Péter Lakatos
October 2015, International journal of immunogenetics,
Bernadett Balla, and Kristóf Árvai, and Péter Horváth, and Bálint Tobiás, and István Takács, and Zsolt Nagy, and Magdolna Dank, and György Fekete, and János P Kósa, and Péter Lakatos
January 2014, Forensic science international. Genetics,
Bernadett Balla, and Kristóf Árvai, and Péter Horváth, and Bálint Tobiás, and István Takács, and Zsolt Nagy, and Magdolna Dank, and György Fekete, and János P Kósa, and Péter Lakatos
December 2020, The Journal of international medical research,
Bernadett Balla, and Kristóf Árvai, and Péter Horváth, and Bálint Tobiás, and István Takács, and Zsolt Nagy, and Magdolna Dank, and György Fekete, and János P Kósa, and Péter Lakatos
November 2016, Forensic science international. Genetics,
Copied contents to your clipboard!